Advantage Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Advantage Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$214K	Hold	7,874	–	–	0.17%	140
2019 Q2	$189K	Hold	7,874	–	–	0.14%	150
2019 Q1	$208K	Hold	7,874	–	–	0.16%	141
2018 Q4	$154K	Hold	7,874	–	–	0.12%	172
2018 Q3	$154K	Hold	7,874	–	–	0.1%	186
2018 Q2	$130K	Hold	7,874	–	–	0.1%	183
2018 Q1	$112K	Hold	7,874	–	–	0.04%	229
2017 Q4	$115K	Hold	7,874	–	–	0.04%	246
2017 Q3	$100K	Buy	7,874 +4,900	+165%	+$62.3K	0.03%	251
2017 Q2	$35K	Hold	2,974	–	–	0.01%	465
2017 Q1	$44K	Sell	2,974 -125	-4%	-$2.02K	0.02%	370
2016 Q4	$50K	Sell	3,099 -1,078	-26%	-$19.5K	0.02%	329
2016 Q3	$76K	Sell	4,177 -2,000	-32%	-$39.1K	0.03%	259
2016 Q2	$102K	Sell	6,177 -561	-8%	-$9.08K	0.05%	224
2016 Q1	$112K	Hold	6,738	–	–	0.05%	206
2015 Q4	$146K	Hold	6,738	–	–	0.08%	170
2015 Q3	$134K	Buy	6,738 +3,579	+113%	+$113K	0.08%	162
2015 Q2	$110K	Sell	3,159 -1,192	-27%	-$36.4K	0.05%	224
2015 Q1	$113K	Hold	4,351	–	–	0.06%	218
2014 Q4	$56K	Buy	+4,351	New	+$54.5K	0.04%	290

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Advantage Investment Management's HZNP Position: Q3 2019 in Review

Advantage Investment Management held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q3 2019 at 7,874 shares worth $214K. The position accounts for 0.17% of the portfolio, ranked #140.

Advantage Investment Management first reported a position in HZNP in Q4 2014 and has held it in 20 quarters since. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

Advantage Investment Management held 7,874 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $214K as of Q3 2019.
Advantage Investment Management left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q3 2019.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.17% of Advantage Investment Management's portfolio in Q3 2019, its #140 holding.
Advantage Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and has held it in 20 quarters since.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.